Keyphrases
Patients with Schizophrenia
69%
Antipsychotics
64%
Dose Reduction
37%
Specialty Clinic
32%
Long-acting Injectable Antipsychotics
32%
Motivation
32%
Patient Perspective
32%
Clozapine Treatment
32%
Scoping Review
32%
Antipsychotic Polypharmacy
32%
Schizophrenia Spectrum Disorders
32%
Clozapine
32%
Tolerability
32%
Individual Patient Data Meta-analysis
32%
Systematic Meta-analysis
32%
Clinician Perspectives
32%
Negative Syndrome
27%
Level of Functioning
21%
Antipsychotic Dose
18%
Positive Symptoms
18%
Adverse Effects
14%
Oral Antipsychotics
12%
Previous Experience
12%
Relapse Risk
10%
Predictive Models
10%
Second-generation Antipsychotics
9%
Psychotic Patients
9%
Clinical Global Impression Scale
9%
Embase
8%
Specific Patient
7%
Gaps in Research
7%
Relapse Prevention
6%
Treatment Modalities
6%
Clinically Significant
6%
Discontinuing Treatment
6%
Hospitalization
6%
Pharmacokinetic Properties
6%
Pharmacokinetics
6%
Antipsychotic-free
5%
Schizophrenia
5%
High Prevalence
5%
Symptom Progression
5%
Patients Included
5%
Low Adherence
5%
Clinical Predictors
5%
12-month Follow-up
5%
Chlorpromazine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
100%
Clozapine
64%
Schizophrenia Spectrum Disorder
35%
Treatment-Resistant Schizophrenia
35%
Typical Antipsychotic
32%
Positive Syndrome
32%
Polypharmacy
32%
Glutamic Acid
32%
Pharmacokinetics
32%
4 Aminobutyric Acid
32%
Tolerability
32%
Negative Syndrome
22%
Adverse Event
8%
Psychosis
6%
Prevalence
5%
Side Effect
5%
Chlorpromazine
5%
Agranulocytosis
5%